Drug database

This database contains suggested safety information about the interaction of specific drugs in patients with porphyria. You can search this database by the drug class, drug type, generic name, brand name, or by suggested safety status. If you are unclear of a drug's correct spelling, try entering the first letter(s) of the drug's brand name or generic name. For example, if you are searching for Motrin, try entering an M into the brand name field.
Drug class:
Drug type:
Generic name:
Brand name:
Status:

This information is not intended as a substitute for medical professional help or advice but is to be used only as a reference. Consult your physician regarding any health issue(s) or questions you may have. Please read our Terms & Conditions.

Definitions

OK! = very likely to be safe for prolonged use by individuals with an acute porphyria, based on consistent evidence

OK? = probably safe for prolonged use by individuals with an acute porphyria, based on evidence that is either inconsistent or insufficient to be conclusive

BAD? = probably unsafe for prolonged use by individuals with an acute porphyria, based on evidence that is either inconsistent or insufficient to be conclusive

BAD! = very likely to be unsafe for prolonged use by individuals with an acute porphyria, based on consistent evidence

NO INFO = information insufficient for deriving any conclusion

Acknowledgments

The following individuals, who contributed their knowledge and expertise to the development of this drug list, receive our sincere thanks:

The authors of this list: Bo Zhou and Peter V. Tishler, M. D., Channing Laboratory and Genetics Division, Brigham & Women's Hospital, Boston, MA
Numerous patients with an acute porphyria
Drs. Karl E. Anderson, D. Montgomery Bissell, Joseph R. Bloomer, Herbert L. Bonkovsky
Physicians at Harvard Medical School and/or the Brigham & Women’s Hospital: Ronald A. Arky, Edward B. Bromfield, Dawn L. Demeo, Sunil Eappen, Christopher H. Fanta, Samuel Z. Goldhaber, Norton J. Greenberger, Koenraad J. Mortele, Louis R. Pasquale (Massachusetts Eye & Ear Infirmary), Edgar L. Ross, Judith M. Strymish (VA Boston Healthcare System), Lewis R. Sudarsky, Chinweike Ukumadu, Bernardino Vaccaro, Stephen D. Wiviott
Drs. Barbara W. LeDuc and David A. Williams of the Massachusetts College of Pharmacy and Health Sciences
All individuals who contributed to existent drug lists: the Scandinavian drug database (especially Drs. Atle Brun and Stig Thunell), the University of Cape Town Porphyria Service drug database, the European Porphyria Initiative, and the Porphyria Research Unit of Professor Michael Moore of the University of Queensland
The members of the American Porphyria Foundation for their financial and administrative support
Ms. Nina Zonnevylle of the Brigham & Women’s Hospital (for administrative support)

The APF is not responsible for the interpretive translations in other languages.

The information contained on the American Porphyria Foundation (APF) Web site or in the APF newsletter is provided for your general information only.

The APF does not give medical advice or engage in the practice of medicine. The APF under no circumstances recommends particular treatments for specific individuals, and in all cases recommends that you consult your physician or local treatment center before pursuing any course of treatment.

All information and content on this Web site are protected by copyright. All rights are reserved. Users are prohibited from modifying, copying, distributing, transmitting, displaying, publishing, selling, licensing, creating derivative works, or using any information available on or through the site for commercial or public purposes.

The American Porphyria Foundation (APF) Tax Forms 990 are readily available to the public. If you would like a copy, please contact the APF: 4900 Woodway, Suite 780, Houston, TX 77056. Toll free: 1.866.APF.3635.

Join the APF—Your donations help support patient and physician education as well as porphyria research. Learn more...